Newly diagnosed AML: a second opinion without delaying care

A newly diagnosed acute myeloid leukaemia (AML) referral is time sensitive. An international second opinion can help clarify a diagnosis or treatment plan, but preparing it must run alongside the care the patient needs now. Do not delay an urgent admission, prescribed treatment or assessment of worsening symptoms to organise travel.

First establish who is responsible today

Ask the current haematology team whether the patient should remain in hospital, which immediate care is needed and how quickly a specialist decision must be made. AML can progress rapidly; the NCI emphasises prompt treatment. A scheduled online consultation or a clinic appointment abroad is not an emergency-care arrangement.

If the patient is not yet under a haematologist’s care, follow the urgent referral instructions given locally. Significant bleeding, severe breathlessness, confusion or rapid deterioration warrant immediate local medical attention. The record-transfer process should never become the reason that care is postponed.

Send a minimum useful clinical file promptly

Ask the current doctor to provide a short referral identifying the confirmed diagnosis or current suspicion, the patient’s condition and the question for the reviewing specialist. Attach available blood counts and marrow reports. Include flow cytometry, chromosome and molecular reports if they have resulted; clearly mark pending tests.

A practical index might read: diagnostic marrow, latest blood results, molecular results available, molecular results pending, treatment already started, major complications. This lets the receiving team see the status without assuming that a missing file is a normal result.

Do not confuse incomplete data with a reason to wait indefinitely

Ask both teams which findings are needed for the immediate decision and which can follow. Some results may change later decisions, but that does not mean the family should decide independently to postpone current care. The clinician should explain the timetable and any interim plan.

If the initial discussion concerns a particular AML subtype, preserve the exact wording. A suspicion of acute promyelocytic leukaemia requires urgent specialist attention and should be relayed directly, not placed at the bottom of a general travel enquiry.

Request an actionable written response

• What question can be answered from the available records?
• Which uncertainties remain and who will resolve them?
• Does the reviewing specialist recommend discussion directly with the treating haematologist?
• Is transfer appropriate, and what medical arrangements would it require?

Separate a records-review appointment from acceptance for inpatient treatment. If a transfer is proposed, ask for receiving-team confirmation and a clinical handover plan before any transport booking.

Keep financial arrangements behind clinical readiness

A preliminary quotation may change when the subtype, current condition and support requirements are clearer. Ask what the first assessment covers and which later costs remain conditional. Avoid interpreting a fast quotation as proof that a bed, treatment programme or transfer has been medically approved. The most valuable early result is a safe, timely and clearly assigned next step.

A practical next step

For the practical arrangements, see An oncology second opinion: when it helps and how to prepare.

Sources

• NCI: Acute Myeloid Leukemia Treatment